Page 220 - Drug Class Review
P. 220
Page 140 of 205
Drug Effectiveness Review Project
To compare the efficacy and safety of MEM in patients with moderate to severe AD already receiving
placebo N/A 24 weeks 201 Probable AD by NINCDS; MMSE score of 5 – 14; > 50 yrs old; recent (within 12 months) MRI or CT scan consistent with probable AD; ongoing ChE inhibitor with DON for more than 6 months before entrance into trial and as stable dose (5-10 mg/d) for at least 3 months; reliable caregiver; ambulatory Significant B 12 or folate deficiency; active pulmonary, gastrointestinal, renal, hepatic, endocrine or cardiovascular disease; psychiatric or central nervous system disorders other than AD; dementia complicated by other organic disea
Drugs Authors: Tariot et al. 60 Forest Research Institute, a division of Forest Laboratories Setting: Multi-center (37 sites) memantine 20mg/d titrated in 5 mg/d doses 24 weeks 203 aided ability; residence in community; stable medical condition
Alzheimer Year: 2004 Country: US DON treatment Study design: RCT Sample size: 404
Final Report Update 1 Efficacy/Effectiveness STUDY: FUNDING: RESEARCH OBJECTIVE: DESIGN: INTERVENTION: Dose: Duration: Sample size: INCLUSION: EXCLUSION: OTHER MEDICATIONS/ INTERVENTIONS ALLOWED: Alzheimer's Drugs
